cve: nsp

Naturally Splendid Announces Private Placement

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company") (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) announces a non-brokered private placement financing of up to 100,000,000 Units (each a "Unit") at a price of $0.03 per Unit for gross proceeds of up to $3,000,000 (the "Offering"). The Offering replaces the previously announced private placement offering at $0.05 per unit (see news release dated July 7, 2021

Each Unit in the non-brokered private placement consists of one common share of Naturally Splendid and one common share purchase warrant (each a "Warrant"), with each Warrant entitling the holder to purchase one additional common share for a period of two years from the date of the issue at an exercise price of $0.05 per share.

Proceeds of the Offering will be directed primarily towards purchasing and installing a new manufacturing line, to produce plant-based food entrees as well as for day-to-day operations. This state-of-the-art manufacturing line will be installed in our existing 20,000 square foot manufacturing facility in Pitt Meadows, BC and replicates the manufacturing line currently used in the production facility in Australia, in order to produce the plant-based products currently being imported from Flexitarian Foods Pty. Ltd., a division of Australia's largest plant-based manufacturer.

Funds will also be directed to facility upgrades including an industrial freezer as well as increasing electrical and plumbing infrastructure. These upgrades will take place concurrently while we await the arrival of the new manufacturing line.

Once completed the facility will be capable of manufacturing a wide range of plant-based alternatives for beef, chicken, pork, fish and shellfish. This line is capable of producing ten (10) tons of finished plant-based entrees daily initially. As efficiencies are attained it is expected that this line will produce up to twenty (20) tons of finished plant-based entrees daily.

As reported in an earlier news release, the Company has begun installation of a sophisticated packaging system for NATERA Plant Based products for retail markets, food service and web sales. This versatile packaging system was selected for the range of products and packaging types it is designed to process, thus optimizing the opportunity to penetrate multiple channels.

Leveraging the existing infrastructure of our current production facility and optimizing manufacturing capacity and packaging flexibility is key as we engage with larger food service and retail clients. The upgraded manufacturing facility will provide the platform and wherewithal to acquire larger clients and the maintain a steady supply to meet demand.

Naturally Splendid CEO Mr. J. Craig Goodwin states, "The combination of a new plant-based production line and new packaging line is game changing for Naturally Splendid. This manufacturing and packaging system has been selected for its versatility and capacity. As we engage with larger food service and retail clients, it is essential to be able to meet their demands in packaging options as well as scalability to meet volume demands and this system allows us to do exactly that. Manufacturing ourselves rather than importing has several significant operational advantages including reduced cost per unit, inventory controls and the ability to customize production to meet the requirements of clients in Canada and the United States."

Naturally Splendid may pay finders a fee in cash and/or share purchase warrants in connection with the Offering. There is no minimum amount to the Offering. The Offering will be completed to "accredited investors" pursuant to National Instrument 45-106 - Prospectus and Registration Exemptions ("NI 45-106"), to existing security holders pursuant to BC Instrument 45-534 - Exemption from prospectus requirement from certain trades to existing security holders ("BCI 45-534") and to certain subscribers pursuant to B.C. Instrument 45-536 - Exemptions from prospectus requirement for certain distributions through an investment dealer. The Offering of securities pursuant to BCI 45-534 is being made to existing security holders who held shares of Naturally Splendid on November 16, 2021 (the "Record Date"). Naturally Splendid confirms that there is no material fact or material change regarding Naturally Splendid that has not been generally disclosed. In the event that Naturally Splendid receives subscriptions above the maximum, Naturally Splendid will adjust the subscriptions received on a pro-rata basis.

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. J. Craig Goodwin

CEO, President, Director

Contact Information
Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE:Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/673464/Naturally-Splendid-Announces-Private-Placement

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares.

All matters put forward to shareholders for consideration and approval, as set out in the Company's Management Information Circular dated 22nd of February, 2024, were approved by the requisite majority of votes cast at the Meeting. These were:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

120-Day Business Development Plan

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company’s CEO Matthew Leonard and CFO Chow Yee Koh are currently travelling in Malaysia and China for a series of meetings over a 2–3- week period commencing last week. The CEO and CFO will be joined by China-based Company Director Michael Huang for strategic meetings in Malaysia and China.

Keep reading...Show less
  BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

Keep reading...Show less
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting (GBC). This marks a crucial step in Sirona Biochem's plan to offer innovative skincare solutions.

The chosen formulation will not only define the brand but also lay the foundation for a broader range of products. The team is in the process of selecting the precise formulation that will undergo standard safety evaluations and be used in the upcoming clinical trial. This is in preparation for the planned product launch in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
double helix molecule with word "etf"

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to gain leverage in multiple biotech companies via one investment vehicle.

The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small biotech ETFs for investors to consider. They were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of March 8, 2024. All other figures were also current as of that date. Read on to learn more about these investment vehicles.

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® AT AAD 2024

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis

Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×